A large Cochrane review is challenging one of the most persistent assumptions in preventive gastroenterology: that aspirin meaningfully reduces colorectal cancer (CRC) risk in average-risk populations. Across nearly 125,000 participants from randomized trials, aspirin showed little to no impact on CRC incidence over 5–15 years, with any potential benefit appearing only after more than a decade—and even then, the evidence remains uncertain.
Aspirin Unlikely to Cut Colorectal Cancer Incidence (Medscape)
0